Sanofi

6,221.50
+14.50
(0.23%)
Market Cap
14,328.50 Cr
EPS
261.78
PE Ratio
39.43
Dividend Yield
1.88 %
Industry
Healthcare
52 Week High
10,524.95
52 Week Low
4,902.00
PB Ratio
16.60
Debt to Equity
0.02
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from2 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+100.00 %
+100.00 %
Hold
Hold0.0 %
0.0 %
Sell
Sell0.0 %
0.0 %

Company News

View All News
Caret
neutral
Sanofi India Clarifies No Plans to Divest Insulin Brand Lantus2 days ago
Sanofi India has issued a clarification regarding a news article about its insulin brand Lantus. The company explicitly stated that it has no intentions to divest, sell, or license the Lantus brand.
Competitors LTP Market Cap (₹ Cr.) P/E Ratio Revenue (₹ Cr.) YoY Revenue Growth % Net Profit (₹ Cr.) YoY Profit Growth % RSI
1,751.50
#1 4,20,243.52
34.43
#1 49,887.20
12.06
#1 9,648
13.77
56.15
5,640.00
1,49,724.28
73.95
8,184.00
0.89
1,600
#1 64.53
49.32
1,515.20
1,22,369.82
24.22
26,520.70
14.17
4,155
47.38
58.14
3,254.80
1,10,157.22
58.55
10,785.70
11.59
1,656
13.54
57.00
2,581.60
1,06,511.27
50.98
10,615.60
19.57
1,942
-16.38
65.51
1,163.60
97,097.23
#1 18.01
28,905.40
12.36
5,578
1.69
53.92
1,937.20
88,441.11
30.81
20,141.50
#1 19.94
1,936
38.82
44.61
831.55
83,673.39
18.24
19,831.50
13.82
3,831
29.92
39.09
1,171.60
68,046.72
18.66
29,559.20
17.55
3,169
-10.04
56.33
30,690.00
65,214.11
48.91
6,097.20
10.80
1,201
16.01
56.24
Growth Rate
Revenue Growth
-
Net Income Growth
-
Cash Flow Change
-97.69 %
ROE
-
ROCE
-
EBITDA Margin (Avg.)
-

Quarterly Financial Results

Quarterly Financials
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Revenue
622
572
573
547
579
503
526
529
Expenses
368
393
377
370
400
367
404
397
EBITDA
254
179
195
177
179
137
122
132
Operating Profit %
29 %
24 %
23 %
21 %
22 %
21 %
23 %
23 %
Depreciation
9
9
9
9
9
9
9
10
Interest
0
1
0
0
0
0
0
0
Profit Before Tax
244
169
186
167
169
127
113
122
Tax
54
46
34
30
33
24
30
31
Net Profit
190
123
152
138
137
103
82
91
EPS in ₹
82.78
53.37
65.95
59.79
59.31
44.81
35.69
39.64

Balance Sheet

Balance Sheet
2023
Total Assets
1,715
Fixed Assets
315
Current Assets
1,248
Capital Work in Progress
16
Investments
0
Other Assets
1,384
Total Liabilities
1,715
Current Liabilities
651
Non Current Liabilities
48
Total Equity
1,015
Reserve & Surplus
992
Share Capital
23

Cash Flow

Cash Flow
2023
Net Cash Flow
-610
Investing Activities
38
Operating Activities
230
Financing Activities
-878

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Promoter
60.40 %
60.40 %
60.40 %
60.40 %
60.40 %
60.40 %
60.40 %
60.40 %
60.40 %
60.40 %
60.40 %
60.40 %
60.40 %
60.40 %
60.40 %
60.40 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
6.80 %
0.00 %
6.11 %
5.81 %
5.78 %
5.63 %
DIIs
17.16 %
17.39 %
17.65 %
19.03 %
18.65 %
18.60 %
18.27 %
19.21 %
19.47 %
19.66 %
21.69 %
22.47 %
23.08 %
22.79 %
22.82 %
22.93 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
6.97 %
7.09 %
7.21 %
7.01 %
7.65 %
7.92 %
8.81 %
9.13 %
9.29 %
8.89 %
8.60 %
8.09 %
7.97 %
8.31 %
8.21 %
8.33 %
Others
15.48 %
15.12 %
14.74 %
13.56 %
13.30 %
13.09 %
12.53 %
11.26 %
10.85 %
11.05 %
2.51 %
9.04 %
2.44 %
2.69 %
2.79 %
2.70 %
No of Share Holders
0
48,465
53,567
51,646
50,916
59,276
64,542
73,734
76,694
71,513
68,598
62,870
61,849
67,662
66,211
66,401

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 71 84 349 365 490 570 167 0.00 0.00
Dividend Yield (%) 0.00 1.37 1.44 5.58 4.63 6.53 10.15 2.06 0.00 0.00

Corporate Action

Announcements

Announcement under Regulation 30 (LODR)-Newspaper Publication1 day ago
Rumour verification - Regulation 30(11)2 days ago
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 20188 days ago
Announcement under Regulation 30 (LODR)-Change in Directorate8 days ago
Announcement under Regulation 30 (LODR)-Resignation of Managing Director8 days ago
Closure of Trading WindowApr 04, 2025
Closure of Trading WindowApr 04, 2025
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Apr 02, 2025
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Apr 02, 2025
Announcement under Regulation 30 (LODR)-Dividend UpdatesMar 18, 2025
Announcement under Regulation 30 (LODR)-Change in DirectorateMar 18, 2025
Record Date For Final Dividend For The Financial Year Ended 31St December 2024Mar 18, 2025
Board Meeting Outcome for Outcome Of The Meeting Of The Board Held On 18Th March 2025Mar 18, 2025
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Mar 13, 2025
Announcement Under Regulation 30 (LODR)-Newspaper PublicationMar 12, 2025
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Mar 03, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMar 01, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceFeb 28, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceFeb 28, 2025
Integrated Filing (Financial)Feb 28, 2025
Integrated Filing (Financial)Feb 28, 2025
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 28, 2025
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 28, 2025
Announcement under Regulation 30 (LODR)-Dividend UpdatesFeb 27, 2025
Announcement under Regulation 30 (LODR)-Dividend UpdatesFeb 27, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 27, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 27, 2025
Financial Results For The Financial Year Ended 31St December 2024Feb 27, 2025
Financial Results For The Financial Year Ended 31St December 2024Feb 27, 2025
Board Meeting Outcome for Board Meeting Outcome For Standalone And Consolidated Financial Results For The Quarter And Year Ended 31St December 2024 And Recommendation Of Final DividendFeb 27, 2025
Board Meeting Outcome for Board Meeting Outcome For Standalone And Consolidated Financial Results For The Quarter And Year Ended 31St December 2024 And Recommendation Of Final DividendFeb 27, 2025
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 22, 2025
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 21, 2025
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 19, 2025
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 18, 2025
Board Meeting Intimation for Consideration And Approval Of The Audited Financial Statements (Standalone & Consolidated) For The Quarter And Financial Year Ended 31St December 2024 And Recommendation OFeb 13, 2025
Appointment of Company Secretary and Compliance OfficerFeb 11, 2025
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 05, 2025
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jan 22, 2025
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Jan 08, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 06, 2025
Change Of Name Of Registrar And Transfer Agent Of The CompanyJan 02, 2025
Closure of Trading WindowDec 27, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateDec 09, 2024
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015Nov 27, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateNov 25, 2024
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015Nov 13, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateNov 13, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 08, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateNov 08, 2024

Technical Indicators

RSI(14)
Neutral
65.60
ATR(14)
Less Volatile
188.04
STOCH(9,6)
Overbought
85.73
STOCH RSI(14)
Neutral
61.46
MACD(12,26)
Bullish
17.24
ADX(14)
Strong Trend
32.21
UO(9)
Bearish
62.98
ROC(12)
Uptrend And Accelerating
6.48
WillR(14)
Overbought
-10.83

About Sanofi

Sanofi India Limited is a pharmaceutical company primarily engaged in manufacturing and trading drugs and pharmaceuticals. It operates manufacturing facilities in Goa and Ankleshwar, Gujarat, and sells products through independent distributors mainly in India. The company focuses on five therapeutic areas: diabetes, epilepsy, cardiology, allergy, and pain care. Key products include Lantus (insulin), Combiflam (pain relief), Amaryl (anti-diabetic), Allegra (allergy), Cardace (cardiovascular), and Toujeo (long-acting insulin). Sanofi India is majority-owned by Sanofi and its subsidiary Hoechst GmbH, holding 60.37% of its paid-up share capital. The company has undergone several name changes and acquisitions, including the purchase of Universal Medicare's nutraceutical business in 2011. In 2021, Sanofi India sold its Nutraceuticals business to Universal Nutriscience Private Limited, and in 2022-23, its Consumer Healthcare Business was demerged into a wholly-owned subsidiary.
Chairperson NameAditya Narayan